EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Improvements in Real‐World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment

Thuy N Ho, Patrick Willard, Graeme F Murray iD, Li Liu iD, Nolan Wages, Hyun Lee, Keri R Maher iD

European Journal of Haematology · 2026-04 · 116 (4) · 416-424

DOI: 10.1111/ejh.70087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 23.12.2025. Verfasst von Thuy N Ho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University, Massey Comprehensive Cancer Center, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Virginia Commonwealth University, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic options for newly diagnosed (ND) acute myeloid leukemia (AML) have increased in recent years, leading to a shift in the treatment paradigm from conventional, intensive chemotherapy toward targeted and less intensive therapy. Since 2017, there has been a surge in FDA approvals for novel therapies, including small molecule inhibitors and new combinations of chemotherapy and targeted drugs. It is unclear what effect these changes have had on overall survival in the real‐world clinical setting over time. We retrospectively analyzed 501 patients with ND AML treated at an urban academic cancer center from 2015 to 2022 with respect to survival rates and treatment regimen utilization trends over time, in the context of AML risk category and whether allogeneic stem cell transplantation (HSCT) occurred. Among European LeukemiaNet 2022 intermediate risk ND AML patients who did not undergo HSCT, overall survival and relapse‐free survival improved significantly in the early versus later cohort (2015–2018 vs. 2019–2022, respectively). These gains were not observed in the adverse‐risk subgroup, where outcomes remain unchanged. First‐line use of hypomethylating agent‐based therapies increased seven‐fold, while reliance on chemotherapy alone decreased by half. These findings highlight a meaningful shift in treatment patterns associated with improved outcomes overall, but an ongoing lack of progress in the highest‐risk subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedAdultRetrospective StudiesHematopoietic Stem Cell TransplantationTreatment OutcomeYoung AdultCombined Modality TherapyDisease ManagementTransplantation, HomologousAdolescent

Stichwörter der Autor:innen

acute myeloid leukemiainduction chemotherapymolecular targeted therapysurvival analysis

Autor:innen und Institutionen

  • Virginia Commonwealth University, Massey Comprehensive Cancer Center, Richmond, Virginia, USA.
  • Huntington Health, An Affiliate of Cedars-Sinai, Huntington Hospital, Pasadena, California, USA.

ORCID-Profile: Graeme F Murray, Li Liu, Keri R Maher

Förderung

  • Virginia Commonwealth University
  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Ho, T. N., Willard, P., Murray, G. F., Liu, L., Wages, N., Lee, H., & Maher, K. R. (2026). Improvements in Real‐World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment. European Journal of Haematology, 116(4), 416-424. https://doi.org/10.1111/ejh.70087

Vancouver

Ho TN, Willard P, Murray GF, Liu L, Wages N, Lee H, et al. Improvements in Real‐World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment. European Journal of Haematology. 2026;116(4):416-424. doi:10.1111/ejh.70087

BibTeX
@article{Ho2026,
  author = {Ho, Thuy N and Willard, Patrick and Murray, Graeme F and Liu, Li and Wages, Nolan and Lee, Hyun and Maher, Keri R},
  title = {Improvements in Real‐World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {116},
  number = {4},
  pages = {416--424},
  doi = {10.1111/ejh.70087}
}
Kostenlos starten →